SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
Notice of
HY results
Newcastle, UK - 8 March 2024 - SkinBioTherapeutics plc,
(AIM: SBTX), the life science business focused on skin health,
announces that the Company's interim financial results for the six
months to
31 December 2023 will be released on Friday 22
March 2024.
The results will be available via the
London Stock Exchange's Regulatory News Service (RNS) and on the
Investor Relations section of the Company's website:
www.skinbiotherapeutics.com.
Stuart Ashman, CEO, and Manprit
Randhawa, CFO will provide a live presentation via the
Investor Meet Company platform at 12 noon on Friday 22 March
2024.
Questions can be submitted pre-event
via the Investor Meet Company dashboard up to the day before the
meeting or at any time during the live presentation. Investors who
already follow SkinBioTherapeutics on the Investor Meet Company
platform will automatically be invited.
Investors can sign up to Investor
Meet Company for free at
www.investormeetcompany.com/companies/skinbiotherapeutics-plc.
-Ends-
For
more information please contact:
|
SkinBioTherapeutics plc
Stuart J. Ashman, CEO
Manprit Randhawa, CFO
|
Tel: +44 (0) 191 495
7325
|
|
Cavendish Capital Markets Limited
(Nominated Adviser & Broker)
Giles Balleny, Dan Hodkinson
(Corporate Finance)
Charlie Combe (Broking)
Dale Bellis, Tamar Cranford-Smith
(Sales)
|
Tel: +44 (0) 20 7220
0500
|
|
Instinctif Partners (Media)
Melanie Toyne-Sewell / Jack
Kincade
|
Tel: +44 (0) 20 7457
2020
SkinBioTherapeutics@instinctif.com
|
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life
science company focused on skin health. The Company's proprietary
platform technology, SkinBiotix®, is based upon discoveries made by
Professor Catherine O'Neill and Professor Andrew McBain.
The Company is targeting a number of
skin healthcare sectors, the most advanced of which are cosmetic
skincare and food supplements to modulate the immune system by
harnessing the gut-skin axis. In each area SkinBioTherapeutics
plans to exemplify its technology through human studies. The
Company's first product, AxisBiotix-Ps™, a food supplement to
address the symptoms of mild to moderate psoriasis.
The Company listed on AIM in April
2017 and is based in Newcastle, UK. For more information,
visit: www.skinbiotherapeutics.com and
www.axisbiotix.com.